Compare SILO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SILO | RDHL |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.7K | 4.2M |
| IPO Year | 2011 | 2012 |
| Metric | SILO | RDHL |
|---|---|---|
| Price | $3.20 | $0.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 35.8K | 33.8K |
| Earning Date | 05-13-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $72,102.00 | N/A |
| Revenue This Year | $1.86 | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.58 |
| 52 Week High | $7.95 | $2.79 |
| Indicator | SILO | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 30.99 | 38.14 |
| Support Level | $0.30 | $0.58 |
| Resistance Level | $4.80 | $1.07 |
| Average True Range (ATR) | 0.39 | 0.05 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 17.56 | 14.36 |
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.